Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review

References

• Jin Y, Li Y, Pan L. The target therapy of ovarian clear cell carcinoma. OTT. 2014;1647. doi:10.2147/OTT.S49993
   Google Scholar
• Khalique S, Lord CJ, Banerjee S, Natrajan R. Translational genomics of ovarian clear cell carcinoma. Semin Cancer Biol. 2020;61:121–131. doi:10.1016/j.semcancer.2019.10.025
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA a Cancer J Clin. 2019. doi:10.3322/caac.21559
   PubMed Web of Science ®Google Scholar
• Skirnisdottir I, Bjersand K, Åkerud H, Seidal T. Napsin A as a marker of clear cell ovarian carcinoma. BMC Cancer. 2013;13(1):524. doi:10.1186/1471-2407-13-524
   PubMedGoogle Scholar
• Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105(2):404–408. doi:10.1016/j.ygyno.2006.12.024
   PubMed Web of Science ®Google Scholar
• Hogen L, Vicus D, Ferguson SE, et al. Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma. Int J Gynecol Cancer. 2019;29(7):1164–1169. doi:10.1136/ijgc-2019-000287
   PubMed Web of Science ®Google Scholar
• Oda K, Hamanishi J, Matsuo K, Hasegawa K. Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management. Gynecol Oncol. 2018;151(2):381–389. doi:10.1016/j.ygyno.2018.09.001
   PubMed Web of Science ®Google Scholar
• Taylor SE, Chu T, Elvin JA, Edwards RP, Zorn KK. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol. 2020;156(1):32–37. doi:10.1016/j.ygyno.2019.10.029
   PubMed Web of Science ®Google Scholar
• Lheureux S, Tinker AV, Clarke BA, et al. A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the princess margaret phase II consortium. Clin Cancer Res. 2018;24(24):6168–6174. doi:10.1158/1078-0432.CCR-18-1244
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. JCO. 2015;33:4015–4022. doi:10.1200/JCO.2015.62.3397
   PubMed Web of Science ®Google Scholar
• Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. J Clin Oncol. 2016. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.5533. Accessed June 12, 2020.
   Google Scholar
• Lee J-M, Cimino-Mathews A, Peer CJ, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1–3 inhibitor cediranib in women’s cancers: a dose-escalation, Phase I Study. J Clin Oncol. 2017;35:2193–2202. doi:10.1200/JCO.2016.72.1340
   PubMed Web of Science ®Google Scholar
• Bellone S, Buza N, Choi J, et al. Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement. Clin Cancer Res. 2018;24:3282–3291. doi:10.1158/1078-0432.CCR-17-1805
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080–1087. doi:10.1093/annonc/mdz135
   PubMed Web of Science ®Google Scholar
• Zhang G, Liu C, Bai H, Cao G, Cui R, Zhang Z. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment. Oncol Lett. 2019;17:2583–2591. doi:10.3892/ol.2019.9902
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690–714. doi:10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Ribas A, Lawrence D, Atkinson V, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019;25:936–940. doi:10.1038/s41591-019-0476-5
   PubMed Web of Science ®Google Scholar
• Günther A, Baumann P, Burger R, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica. 2015;100:541–547. doi:10.3324/haematol.2014.116269
   PubMed Web of Science ®Google Scholar
• de Melo AC, Paulino E, Garces ÁHI. A review of mTOR pathway inhibitors in gynecologic cancer. Oxid Med Cell Longev. 2017;2017:4809751. doi:10.1155/2017/4809751
   PubMed Web of Science ®Google Scholar
• Willis BC, Sloan EA, Atkins KA, Stoler MH, Mills AM. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol. 2017;30(11):1622–1632. doi:10.1038/modpathol.2017.67
   PubMed Web of Science ®Google Scholar
• Zhu J, Wen H, Bi R, Wu Y, Wu X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol. 2017;28(6). doi:10.3802/jgo.2017.28.e77
   Web of Science ®Google Scholar
• Li M, Li H, Liu F, et al. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res. 2017;10(1). doi:10.1186/s13048-017-0304-9
   Google Scholar
• Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF -mutant melanoma: promise and challenges. JCO. 2014;32(21):2248–2254. doi:10.1200/JCO.2013.52.1377
   PubMed Web of Science ®Google Scholar
• Bergström M, Müller M, Karlsson M, Scholz H, Vethe NT, Korsgren O. Comparing the effects of the mTOR inhibitors azithromycin and rapamycin on in vitro expanded regulatory T cells. Cell Transplant. 2019;28(12):1603–1613. doi:10.1177/0963689719872488
   PubMed Web of Science ®Google Scholar
• Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can treg cells be a new therapeutic target? Cancer Sci. 2019;110:2080–2089. doi:10.1111/cas.14069
   PubMed Web of Science ®Google Scholar
• Lastwika KJ, Wilson W, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non–small cell lung cancer. Cancer Res. 2016;76(2):227–238. doi:10.1158/0008-5472.CAN-14-3362
   PubMed Web of Science ®Google Scholar
• Moore EC, Cash HA, Caruso AM, et al. Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol Res. 2016;4(7):611–620. doi:10.1158/2326-6066.CIR-15-0252
   PubMed Web of Science ®Google Scholar
• Aqbi HF, Wallace M, Sappal S, Payne KK, Manjili MH. IFN-γ orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol. 2018;103(6):1219–1223. doi:10.1002/JLB.5MIR0917-351R
   Web of Science ®Google Scholar
• Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 2012;366(9):866–868. doi:10.1056/NEJMc1114329
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–1366. doi:10.1056/NEJMc1302338
   PubMed Web of Science ®Google Scholar